hVIVO’s (HVO) “Hold” Rating Reaffirmed at Stifel Nicolaus

hVIVO (LON:HVO)‘s stock had its “hold” rating reaffirmed by investment analysts at Stifel Nicolaus in a research note issued to investors on Wednesday,Digital Look reports. They presently have a GBX 10 price objective on the stock. Stifel Nicolaus’ price target suggests a potential upside of 18.34% from the stock’s previous close.

Separately, Shore Capital Group reaffirmed a “buy” rating and set a GBX 25 price target on shares of hVIVO in a research note on Thursday, January 29th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, hVIVO currently has an average rating of “Moderate Buy” and an average target price of GBX 15.

hVIVO Trading Down 2.9%

Shares of hVIVO stock traded down GBX 0.25 during mid-day trading on Wednesday, hitting GBX 8.45. 7,143,294 shares of the stock were exchanged, compared to its average volume of 3,338,046. hVIVO has a twelve month low of GBX 4.31 and a twelve month high of GBX 19.50. The stock has a market capitalization of £58.17 million, a price-to-earnings ratio of 10.97 and a beta of 1.67. The company has a 50-day simple moving average of GBX 7.66 and a 200 day simple moving average of GBX 6.80. The company has a current ratio of 1.60, a quick ratio of 1.16 and a debt-to-equity ratio of 33.70.

hVIVO (LON:HVO) last released its quarterly earnings results on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 11.97% and a net margin of 10.37%.The firm had revenue of GBX 4,677 million for the quarter. Research analysts forecast that hVIVO will post 1.5492958 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.